在一名接受慢性中心血液透析的终末期肾病患者中，出现严重急性呼吸综合征冠状病毒2（SARS-CoV-2）IgG抗体后感染了2019冠状病毒病。抗体检测存在再次感染或不准确的情况。
COVID-19 in a patient with end-stage renal disease on chronic in-center hemodialysis after evidence of SARS-CoV-2 IgG antibodies. Reinfection or inaccuracy of antibody testing.
作者信息
Munoz Mendoza Jair, Alcaide Maria L
机构信息
1120 NW 14th St. Suite 809, Katz Family Division of Nephrology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
1120 NW 14th St. Suite 849, Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, 33136, USA.
出版信息
IDCases. 2020;22:e00943. doi: 10.1016/j.idcr.2020.e00943. Epub 2020 Sep 6.
Abstract
A patient with end-stage renal disease on hemodialysis with a previous positive SARS-CoV-2 IgG antibody was diagnosed with severe COVID-19. Issues regarding reinfection, the potential lack of antibody protection after asymptomatic infection, the possibility of antibody dependent enhancement and careful interpretation of antibody test results are discussed.
摘要
一名接受血液透析的终末期肾病患者，此前SARS-CoV-2 IgG抗体呈阳性，被诊断为重症新型冠状病毒肺炎。文中讨论了再感染问题、无症状感染后可能缺乏抗体保护、抗体依赖增强的可能性以及抗体检测结果的谨慎解读。
相似文献
1
COVID-19 in a patient with end-stage renal disease on chronic in-center hemodialysis after evidence of SARS-CoV-2 IgG antibodies. Reinfection or inaccuracy of antibody testing.在一名接受慢性中心血液透析的终末期肾病患者中，出现严重急性呼吸综合征冠状病毒2（SARS-CoV-2）IgG抗体后感染了2019冠状病毒病。抗体检测存在再次感染或不准确的情况。
IDCases. 2020;22:e00943. doi: 10.1016/j.idcr.2020.e00943. Epub 2020 Sep 6.
2
A Cell-Based ELISA to Improve the Serological Analysis of Anti-SARS-CoV-2 IgG.一种基于细胞的 ELISA 方法，可改善抗 SARS-CoV-2 IgG 的血清学分析。
Viruses. 2020 Nov 8;12(11):1274. doi: 10.3390/v12111274.
3
SARS-CoV-2 IgG/IgM Rapid Test as a Diagnostic Tool in Hospitalized Patients and Healthcare Workers, at a large Teaching Hospital in northern Italy, during the 2020 COVID-19 Pandemic.2020年新冠疫情期间，在意大利北部一家大型教学医院，将严重急性呼吸综合征冠状病毒2型IgG/IgM快速检测作为住院患者和医护人员的诊断工具。
New Microbiol. 2020 Oct;43(4):161-165. Epub 2020 Oct 31.
4
Epidemiology of SARS-CoV-2 antibodies among firefighters/paramedics of a US fire department: a cross-sectional study.美国消防部门消防员/护理人员中 SARS-CoV-2 抗体的流行病学：一项横断面研究。
Occup Environ Med. 2020 Dec;77(12):857-861. doi: 10.1136/oemed-2020-106676. Epub 2020 Aug 6.
5
Longer Duration of SARS-CoV-2 Infection in a Case of Mild COVID-19 With Weak Production of the Specific IgM and IgG Antibodies.SARS-CoV-2 感染时间延长：COVID-19 轻症患者体内特异性 IgM 和 IgG 抗体产生较弱。
Front Immunol. 2020 Aug 7;11:1936. doi: 10.3389/fimmu.2020.01936. eCollection 2020.
6
[SARS-CoV-2 and Microbiological Diagnostic Dynamics in COVID-19 Pandemic].[严重急性呼吸综合征冠状病毒2与2019冠状病毒病大流行中的微生物诊断动态]
Mikrobiyol Bul. 2020 Jul;54(3):497-509. doi: 10.5578/mb.69839.
7
Antibody Detection and Dynamic Characteristics in Patients With Coronavirus Disease 2019.新型冠状病毒肺炎患者的抗体检测及动态特征。
Clin Infect Dis. 2020 Nov 5;71(8):1930-1934. doi: 10.1093/cid/ciaa461.
8
Anti-SARS-CoV-2 IgG antibody response among Indian COVID-19 patients using β-propiolactone-inactivated, whole virus-based indirect ELISA.使用β-丙内酯灭活、基于全病毒的间接 ELISA 检测印度 COVID-19 患者的抗 SARS-CoV-2 IgG 抗体反应。
J Virol Methods. 2021 Jan;287:113996. doi: 10.1016/j.jviromet.2020.113996. Epub 2020 Oct 22.
9
[The prevalence rate of anti-SARS-CoV-2-IgG is 1.2% - Screening in asymptomatic outpatients in Germany (Northrhine-Westfalia)].[抗SARS-CoV-2-IgG的流行率为1.2%——德国（北莱茵-威斯特法伦州）无症状门诊患者筛查]
MMW Fortschr Med. 2020 Aug;162(14):44-46. doi: 10.1007/s15006-020-0750-y.
10
Testing for COVID-19: a few points to remember.新冠病毒检测：几点需要记住的事项。
Cas Lek Cesk. 2020 Spring;159(2):72-77.
引用本文的文献
1
SARS-CoV-2 infection on the kidney transplant waiting list: Can a patient be transplanted after COVID-19?肾移植等待名单上的新型冠状病毒2感染：新冠肺炎康复后的患者能否进行移植？
Nefrologia (Engl Ed). 2022 Mar-Apr;42(2):215-217. doi: 10.1016/j.nefroe.2022.04.003. Epub 2022 Apr 18.
2
Clinical and epidemiological features of patients with COVID-19 reinfection: a systematic review.新冠病毒二次感染患者的临床和流行病学特征：一项系统综述
New Microbes New Infect. 2022 Jul;48:101021. doi: 10.1016/j.nmni.2022.101021. Epub 2022 Aug 28.
3
SARS-CoV-2 reinfection across a spectrum of immunological states.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）在一系列免疫状态下的再次感染。
Health Sci Rep. 2022 Jul 22;5(4):e554. doi: 10.1002/hsr2.554. eCollection 2022 Jul.
4
Clinical manifestations, treatment options, and comorbidities in COVID-19 relapse patients: A systematic review.COVID-19 复发患者的临床表现、治疗选择和合并症：系统评价。
J Clin Lab Anal. 2022 May;36(5):e24402. doi: 10.1002/jcla.24402. Epub 2022 Apr 8.
5
A case of COVID-19 Reinfection and Systematic Review of Patterns of Reinfection.一例新冠病毒再次感染病例及再次感染模式的系统综述
Infect Dis Clin Pract (Baltim Md). 2021 Nov;29(6):e409-e411. doi: 10.1097/IPC.0000000000001055. Epub 2021 Aug 4.
6
SARS-CoV-2 Reinfection Is a New Challenge for the Effectiveness of Global Vaccination Campaign: A Systematic Review of Cases Reported in Literature.SARS-CoV-2 再次感染对全球疫苗接种运动的效果构成新挑战：对文献报告病例的系统评价。
Int J Environ Res Public Health. 2021 Oct 19;18(20):11001. doi: 10.3390/ijerph182011001.
7
Rapid decline of anti-SARS-CoV-2 antibodies in patients on haemodialysis: the COVID-FRIAT study.血液透析患者中抗SARS-CoV-2抗体的快速下降：COVID-FRIAT研究
Clin Kidney J. 2021 Mar 9;14(7):1835-1844. doi: 10.1093/ckj/sfab048. eCollection 2021 Jul.
8
Re-infection of SARS-CoV-2: A case in a young dental healthcare worker.新冠病毒再感染：一名年轻牙科医护人员的病例。
J Infect Public Health. 2021 Jun;14(6):685-688. doi: 10.1016/j.jiph.2021.02.012. Epub 2021 Mar 6.
9
SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study.SARS-CoV-2 血清阳性率及健康青年随后的感染风险：一项前瞻性队列研究。
Lancet Respir Med. 2021 Jul;9(7):712-720. doi: 10.1016/S2213-2600(21)00158-2. Epub 2021 Apr 15.
10
SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN).英格兰抗体阳性与抗体阴性医护人员的 SARS-CoV-2 感染率：一项大型、多中心、前瞻性队列研究（SIREN）。
Lancet. 2021 Apr 17;397(10283):1459-1469. doi: 10.1016/S0140-6736(21)00675-9. Epub 2021 Apr 9.
本文引用的文献
1
Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19.轻度新冠肺炎患者体内抗SARS-CoV-2抗体的快速衰减
N Engl J Med. 2020 Sep 10;383(11):1085-1087. doi: 10.1056/NEJMc2025179. Epub 2020 Jul 21.
2
Is novel coronavirus 2019 reinfection possible? Interpreting dynamic SARS-CoV-2 test results.新型冠状病毒 2019 年是否可能再次感染？解读动态 SARS-CoV-2 检测结果。
Am J Emerg Med. 2021 Jan;39:256.e1-256.e3. doi: 10.1016/j.ajem.2020.06.079. Epub 2020 Jul 4.
3
Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020.2020年3月23日至5月12日美国10个地点针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）抗体的血清流行率
JAMA Intern Med. 2020 Jul 21. doi: 10.1001/jamainternmed.2020.4130.
4
Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study.西班牙 2020 年人群血清流行病学研究（ENE-COVID）：全国范围内基于人群的血清流行病学研究。
Lancet. 2020 Aug 22;396(10250):535-544. doi: 10.1016/S0140-6736(20)31483-5. Epub 2020 Jul 6.
5
Recurrence or Relapse of COVID-19 in Older Patients: A Description of Three Cases.老年 COVID-19 患者的复发或再发：三例描述。
J Am Geriatr Soc. 2020 Oct;68(10):2179-2183. doi: 10.1111/jgs.16728. Epub 2020 Aug 13.
6
Clinical Validity of Serum Antibodies to SARS-CoV-2 : A Case-Control Study.血清抗 SARS-CoV-2 抗体的临床有效性：一项病例对照研究。
Ann Intern Med. 2020 Oct 20;173(8):614-622. doi: 10.7326/M20-2889. Epub 2020 Jul 6.
7
Clinical recurrences of COVID-19 symptoms after recovery: Viral relapse, reinfection or inflammatory rebound?新冠康复后临床复发的 COVID-19 症状：病毒复发、再感染还是炎症反弹？
J Infect. 2020 Nov;81(5):816-846. doi: 10.1016/j.jinf.2020.06.073. Epub 2020 Jun 30.
8
Epidemiology of COVID-19 in an Urban Dialysis Center.城市透析中心的 COVID-19 流行病学。
J Am Soc Nephrol. 2020 Aug;31(8):1815-1823. doi: 10.1681/ASN.2020040534. Epub 2020 Jun 19.
9
Dengue Fever, COVID-19 (SARS-CoV-2), and Antibody-Dependent Enhancement (ADE): A Perspective.登革热、COVID-19（SARS-CoV-2）和抗体依赖性增强（ADE）：一个视角。
Cytometry A. 2020 Jul;97(7):662-667. doi: 10.1002/cyto.a.24047. Epub 2020 Jun 7.
10
Persistent detection of SARS-CoV-2 RNA in patients and healthcare workers with COVID-19.在 COVID-19 患者和医护人员中持续检测到 SARS-CoV-2 RNA。
J Clin Virol. 2020 Aug;129:104477. doi: 10.1016/j.jcv.2020.104477. Epub 2020 May 30.
Zotero 插件